Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), eaai8504. (doi:10.1126/scitranslmed.aai8504) (PMID:28381539)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), eaai8504. (doi:10.1126/scitranslmed.aai8504) (PMID:28381539)

[img]
Preview
Text
139884.pdf - Accepted Version

4MB

Abstract

The emerging standard of care for patients with inoperable pancreatic cancer is a combination of cytotoxic drugs gemcitabine and Abraxane, but patient response remains moderate. Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response. Little is known about how sequential dual targeting of tumor tissue tension and vasculature before chemotherapy can affect tumor response. We used intravital imaging to assess how transient manipulation of the tumor tissue, or "priming," using the pharmaceutical Rho kinase inhibitor Fasudil affects response to chemotherapy. Intravital Förster resonance energy transfer imaging of a cyclin-dependent kinase 1 biosensor to monitor the efficacy of cytotoxic drugs revealed that priming improves pancreatic cancer response to gemcitabine/Abraxane at both primary and secondary sites. Transient priming also sensitized cells to shear stress and impaired colonization efficiency and fibrotic niche remodeling within the liver, three important features of cancer spread. Last, we demonstrate a graded response to priming in stratified patient-derived tumors, indicating that fine-tuned tissue manipulation before chemotherapy may offer opportunities in both primary and metastatic targeting of pancreatic cancer.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Anderson, Professor Kurt and McGhee, Dr Ewan and Evans, Professor Thomas and Biankin, Professor Andrew and Sansom, Professor Owen
Authors: Vennin, C., Chin, V. T., Warren, S. C., Lucas, M. C., Herrmann, D., Magenau, A., Melenec, P., Walters, S. N., Del Monte-Nieto, G., Conway, J. R.W., Nobis, M., Allam, A. H., McCloy, R. A., Currey, N., Pinese, M., Boulghourjian, A., Zaratzian, A., Adam, A. A.S., Heu, C., Nagrial, A. M., Chou, A., Steinmann, A., Drury, A., Froio, D., Giry-Laterriere, M., Harris, N. L.E., Phan, T., Jain, R., Weninger, W., McGhee, E. J., Whan, R., Johns, A. L., Samra, J. S., Chantrill, L., Gill, A. J., Kohonen-Corish, M., Harvey, R. P., Biankin, A. V., Evans, T.R. J., Anderson, K. I., Grey, S. T., Ormandy, C. J., Gallego-Ortega, D., Wang, Y., Samuel, M. S., Sansom, O. J., Burgess, A., Cox, T. R., Morton, J. P., Pajic, M., and Timpson, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Science Translational Medicine
Publisher:American Association for the Advancement of Science
ISSN:1946-6234
ISSN (Online):1946-6242
Copyright Holders:Copyright © 2017 American Association for the Advancement of Science
First Published:First published in Science Translational Medicine 9(384):eaai8504
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record